Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

NN 3201

Next Previous
Drug Profile

NN 3201

Alternative Names: NN-3201

Latest Information Update: 11 Mar 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novelty Nobility
  • Class Antineoplastics; Auristatins; Drug conjugates; Immunotoxins; Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Adenoid cystic carcinoma; Gastrointestinal stromal tumours; Neuroendocrine tumours; Renal cell carcinoma; Small cell lung cancer; Uveal melanoma
  • Preclinical Solid tumours

Most Recent Events

  • 03 Feb 2025 Phase-I clinical trials in Adenoid cystic carcinoma (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV) (NCT06805825) (Novelty Nobility pipeline, March 2025)
  • 03 Feb 2025 Phase-I clinical trials in Gastrointestinal stromal tumours (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV) (NCT06805825) (Novelty Nobility pipeline, March 2025)
  • 03 Feb 2025 Phase-I clinical trials in Neuroendocrine tumours (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV) (NCT06805825) (Novelty Nobility pipeline, March 2025)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top